A Prospective, Non-interventional Study to Evaluate the Efficacy and Safety of Iptacopan in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) in Routine Clinical Practice in the Russian Federation
Status: Recruiting
Location: See all (8) locations...
Study Type: Observational
SUMMARY
This is a prospective, non-interventional, multicenter study to evaluate the efficacy and safety of iptacopan in patients with PNH in real-world settings in Russia.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥18 years at the start of iptacopan therapy.
• The patient is undergoing treatment with iptacopan.
• The treating physician decided to prescribe iptacopan based on the Summary of Product Characteristics during routine clinical practice, regardless of study participation.
• Provision of written informed consent.
Locations
Other Locations
Russian Federation
Novartis Investigative Site
RECRUITING
Grozny
Novartis Investigative Site
RECRUITING
Krasnodar
Novartis Investigative Site
RECRUITING
Moscow
Novartis Investigative Site
RECRUITING
Murmansk
Novartis Investigative Site
RECRUITING
Saint Petersburg
Novartis Investigative Site
RECRUITING
Saint Petersburg
Novartis Investigative Site
RECRUITING
Syktyvkar
Novartis Investigative Site
RECRUITING
Yuzhno-sakhalinsk
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2025-07-28
Estimated Completion Date: 2028-01-31
Participants
Target number of participants: 100
Treatments
iptacopan
Adults with PNH who started the iptacopan therapy
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals